Advertisement

Current Diabetes Reports

, 19:75 | Cite as

Economics of Beta-Cell Replacement Therapy

  • Cátia Bandeiras
  • Albert J. Hwa
  • Joaquim M. S. Cabral
  • Frederico Castelo Ferreira
  • Stan N. Finkelstein
  • Robert A. GabbayEmail author
Economics and Policy in Diabetes (AA Baig and N Laiteerapong, Section Editors)
  • 63 Downloads
Part of the following topical collections:
  1. Topical Collection on Economics and Policy in Diabetes

Abstract

Purpose of Review

Type 1 diabetes impacts 1.3 million people in the USA with a total direct lifetime medical cost of $133.7 billion. Management requires a mix of daily exogenous insulin administration and frequent glucose monitoring. Decision-making by the individual can be burdensome.

Recent Findings

Beta-cell replacement, which involves devices protecting cells from autoimmunity and allo-rejection, aims at restoring physiological glucose regulation and improving clinical outcomes in patients. Given the significant burden of T1D in the healthcare systems, cost-effectiveness analyses can drive innovation and policymaking in the area.

Summary

This review presents the health economics analyses performed for donor-derived islet transplantation and the possible outcomes of stem cell-derived beta cells. Long-term cost-effectiveness of islet transplantation depends on the engraftment of these transplants, and the expenses and thresholds assumed by healthcare systems in different countries. Early health technology assessment analyses for stem cell-derived beta-cell replacement suggest manufacturing optimization is necessary to reduce upfront costs.

Keywords

Cost-effectiveness Type 1 diabetes Stem cells Early health technology assessment Islet transplant 

Notes

Acknowledgments

C. Bandeiras acknowledges Fundação para a Ciência e a Tecnologia (FCT) for the PhD fellowship PD/BD/105868/2014.

Funding

This study received funding from Institute for Bioengineering and Biosciences from Fundação para a Ciencia e Tecnologia (UID/BIO/04565/2013), and Programa Operacional Regional de Lisboa 2020 (Project No. 007317), and through the project PRECISE (PAC-PRECISE-LISBOA-01-0145-FEDER-016394).

Compliance with Ethical Standards

Conflict of Interest

Albert J. Hwa, Joaquim M.S. Cabral, Frederico Castelo Ferreira, and Stan N. Finkelstein declare that they have no conflict of interest.

Catia Bandeiras reports personal fees from Compass Biomedical (fees paid for registration and poster presentation for two conferences in the field of stem cell bioprocessing [Biotech Week Boston 2017 and ISCT 2018]; the presented works are not related to the field of diabetes, as showcased in this manuscript.

Robert A. Gabbay reports being a consultant for Sanofi and on the Advisory boards for Health Reveal, Onduo, Hygeia, and Lark.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Paschou SA, Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. On type 1 diabetes mellitus pathogenesis. Endocr Connect [Internet]. Bioscientifica Ltd. 2018 [cited 2019 Mar 25];7:R38–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29191919.CrossRefGoogle Scholar
  2. 2.
    Beckstrand M. The distribution of type 1 diabetes onset in the United States by demographic factors. Walden Diss Dr Stud [Internet]. 2015 [cited 2019 Mar 25]; Available from: https://scholarworks.waldenu.edu/dissertations/569.
  3. 3.
    Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract [Internet]. 2018 [cited 2019 Mar 25];138:271–81. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0168822718302031.CrossRefGoogle Scholar
  4. 4.
    Tao B, Pietropaolo M, Atkinson M, Schatz D, Taylor D. Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method. van Baal PHM, editor. PLoS One [Internet]. 2010 [cited 2019 Mar 25];5:e11501. Available from: https://dx.plos.org/10.1371/journal.pone.0011501
  5. 5.
    Bullard KM, Cowie CC, Lessem SE, Saydah SH, Menke A, Geiss LS, et al. Prevalence of diagnosed diabetes in adults by diabetes type - United States, 2016. MMWR Morb Mortal Wkly Rep [Internet]. Centers for Disease Control and Prevention; 2018 [cited 2019 Apr 30];67:359–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29596402
  6. 6.
    Beckwith J, Nyman JA, Flanagan B, Schrover R, Schuurman H-J. A health economic analysis of clinical islet transplantation. Clin Transpl [Internet]. 2012 [cited 2019 Mar 25];26:23–33. Available from: http://doi.wiley.com/10.1111/j.1399-0012.2011.01411.x CrossRefGoogle Scholar
  7. 7.
    Ijzerman M, Wissing T, de Koning E. Early health economic evaluation of bioartificial organs: involving users in the design of the bioartificial pancreas for diabetes. In: Stamatialis D, editor. Biomed Membr (bio)artificial organs. New Jersey: World Scientific Publishing Co. Pte Ltd; 2017.Google Scholar
  8. 8.
    Latres E, Finan DA, Greenstein JL, Kowalski A, Kieffer TJ. Navigating two roads to glucose normalization in diabetes: automated insulin delivery devices and cell therapy. Cell Metab [Internet]. Elsevier; 2019 [cited 2019 Apr 17];29:545–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30840911 CrossRefGoogle Scholar
  9. 9.
    • Jacobson EF, Tzanakakis ES. Who will win: induced pluripotent stem cells versus embryonic stem cells for β cell replacement and diabetes disease modeling? Curr Diab Rep [Internet]. 2018 [cited 2019 Apr 17];18:133. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30343423. This review describes the main factors differentiating the use of induced pluripotent stem cells from embryonic stem cells to be used for beta-cell replacement.
  10. 10.
    • Hwa AJ, Weir GC. Transplantation of macroencapsulated insulin-producing cells. Curr Diab Rep [Internet]. 2018 [cited 2019 Apr 17];18:50. Available from: http://link.springer.com/10.1007/s11892-018-1028-y. This review showcases the different device designs for macroencapsulation of beta cells for transplantation. Engraftment limitations are directly connected to the mass transport limitations in the devices.
  11. 11.
    Banta D. The development of health technology assessment. Health Policy (New York) [Internet]. Elsevier; 2003 [cited 2019 Apr 15];63:121–32. Available from: https://www.sciencedirect.com/science/article/pii/S0168851002000593 CrossRefGoogle Scholar
  12. 12.
    Archibald PR, Williams DJ. Using the cost–effectiveness of allogeneic islet transplantation to inform induced pluripotent stem cell-derived β-cell therapy reimbursement. Regen Med [Internet]. 2015 [cited 2019 Mar 25];10:959–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26563421 CrossRefGoogle Scholar
  13. 13.
    Bottino R, Knoll MF, Knoll CA, Bertera S, Trucco MM. The future of islet transplantation is now. Front Med [Internet]. Frontiers Media SA; 2018 [cited 2019 Apr 15];5:202. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30057900
  14. 14.
    Mount NM, Ward SJ, Kefalas P, Hyllner J. Cell-based therapy technology classifications and translational challenges. Philos Trans R Soc B Biol Sci [Internet]. The Royal Society; 2015 [cited 2019 Apr 15];370:20150017. Available from: http://rstb.royalsocietypublishing.org/lookup/doi/10.1098/rstb.2015.0017Google Scholar
  15. 15.
    Milne C-P, Kaitin KI. Challenge and change at the forefront of regenerative medicine. Clin Ther [Internet]. Elsevier; 2018 [cited 2019 Apr 15];40:1056–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30006070
  16. 16.
    Gamble A, Pepper AR, Bruni A, Shapiro AMJ. The journey of islet cell transplantation and future development. Islets [Internet]. Taylor & Francis; 2018 [cited 2019 Apr 15];10:80–94. Available from: https://www.tandfonline.com/doi/full/10.1080/19382014.2018.1428511
  17. 17.
    Farney AC, Sutherland DER, Opara EC. Evolution of islet transplantation for the last 30 years. Pancreas [Internet]. 2016 [cited 2019 Apr 15];45:8–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26658037
  18. 18.
    Welsch CA, Rust WL, Csete M. Concise review: lessons learned from islet transplant clinical trials in developing stem cell therapies for type 1 diabetes. Stem Cells Transl Med [Internet]. 2019 [cited 2019 Apr 15];8:209–14. Available from: http://doi.wiley.com/10.1002/sctm.18-0156 CrossRefGoogle Scholar
  19. 19.
    Shapiro AMJ, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation. Nat Rev Endocrinol [Internet]. Nature Publishing Group; 2017 [cited 2019 Apr 15];13:268–77. Available from: http://www.nature.com/articles/nrendo.2016.178 CrossRefGoogle Scholar
  20. 20.
    Anazawa T, Okajima H, Masui T, Uemoto S. Current state and future evolution of pancreatic islet transplantation. Ann Gastroenterol Surg [Internet]. John Wiley & Sons, Ltd; 2019 [cited 2019 Apr 15];3:34–42. Available from: http://doi.wiley.com/10.1002/ags3.12214
  21. 21.
    Israni AK, Zaun D, Rosendale JD, Schaffhausen C, Snyder JJ, Kasiske BL. OPTN/SRTR 2016 Annual data report: deceased organ donation. Am J Transplant [Internet]. John Wiley & Sons, Ltd (10.1111); 2018 [cited 2019 Apr 17];18:434–63. Available from: http://doi.wiley.com/10.1111/ajt.14563
  22. 22.
    Ricordi C, Goldstein JS, Balamurugan AN, Szot GL, Kin T, Liu C, et al. National institutes of health-sponsored clinical islet transplantation consortium phase 3 trial: manufacture of a complex cellular product at eight processing facilities. Diabetes [Internet]. American Diabetes Association; 2016 [cited 2019 Apr 17];65:3418–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27465220 CrossRefGoogle Scholar
  23. 23.
    Brennan DC, Kopetskie HA, Sayre PH, Alejandro R, Cagliero E, Shapiro AMJ, Goldstein JS, DesMarais MR, Booher S, Bianchine PJ Long-term follow-up of the Edmonton protocol of islet transplantation in the United States. Am J Transplant [Internet]. 2016 [cited 2019 Apr 17];16:509–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26433206 CrossRefGoogle Scholar
  24. 24.
    Bottino R, Bertera S, Grupillo M, Melvin PR, Humar A, Mazariegos G, et al. Isolation of human islets for autologous islet transplantation in children and adolescents with chronic pancreatitis. J Transp Secur [Internet]. Hindawi; 2012 [cited 2019 Apr 17];2012:1–8. Available from: http://www.hindawi.com/journals/jtrans/2012/642787/ CrossRefGoogle Scholar
  25. 25.
    Moassesfar S, Masharani U, Frassetto LA, Szot GL, Tavakol M, Stock PG, Posselt AM A comparative analysis of the safety, efficacy, and cost of islet versus pancreas transplantation in nonuremic patients with type 1 diabetes. Am J Transplant [Internet]. 2016 [cited 2019 Mar 25];16:518–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26595767 CrossRefGoogle Scholar
  26. 26.
    Schive SW, Foss A, Sahraoui A, Kloster-Jensen K, Hafsahl G, Kvalheim G, et al. Cost and clinical outcome of islet transplantation in Norway 2010–2015. Clin Transplant [Internet]. John Wiley & Sons, Ltd (10.1111); 2017 [cited 2019 Apr 16];31:e12871. Available from: http://doi.wiley.com/10.1111/ctr.12871
  27. 27.
    Wallner K, Shapiro AMJ, Senior PA, McCabe C. Cost effectiveness and value of information analyses of islet cell transplantation in the management of ‘unstable’ type 1 diabetes mellitus. BMC Endocr Disord [Internet]. 2016 [cited 2019 Mar 25];16:17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27061400
  28. 28.
    Guignard AP, Oberholzer J, Benhamou P-Y, Touzet S, Bucher P, Penfornis A, et al. Cost analysis of human islet transplantation for the treatment of type 1 diabetes in the Swiss-French Consortium GRAGIL. Diabetes Care [Internet]. American Diabetes Association; 2004 [cited 2019 Apr 16];27:895–900. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15047645
  29. 29.
    American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care [Internet]. 2018 [cited 2019 Mar 25];41:917–28. Available from: http://care.diabetesjournals.org/lookup/doi/10.2337/dci18-0007
  30. 30.
    McEwen LN, Casagrande SS, Kuo S, Herman WH. Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost? Curr Diab Rep [Internet]. Springer US; 2017 [cited 2019 Apr 16];17:71. Available from: http://link.springer.com/10.1007/s11892-017-0893-0
  31. 31.
    Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. Pharmacoeconomics [Internet]. Springer; 2018 [cited 2019 Jun 26];36:745–58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29779120 CrossRefGoogle Scholar
  32. 32.
    Lablanche S, David-Tchouda S, Margier J, Schir E, Wojtusciszyn A, Borot S, Kessler L, Morelon E, Thivolet C, Pattou F, Vantyghem MC, Berney T, Benhamou PY Randomised, prospective, medico-economic nationwide French study of islet transplantation in patients with severely unstable type 1 diabetes: the STABILOT study protocol. BMJ Open [Internet]. 2017 [cited 2019 Apr 16];7:e013434. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28219959 CrossRefGoogle Scholar
  33. 33.
    Schulz TC, Young HY, Agulnick AD, Babin MJ, Baetge EE, Bang AG, et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. Lynn FC, editor. PLoS One [Internet]. Public Library of Science; 2012 [cited 2019 Mar 16];7:e37004. Available from: https://dx.plos.org/10.1371/journal.pone.0037004
  34. 34.
    Agulnick AD, Ambruzs DM, Moorman MA, Bhoumik A, Cesario RM, Payne JK, et al. Insulin-producing endocrine cells differentiated in vitro from human embryonic stem cells function in macroencapsulation devices in vivo. Stem Cells Transl Med [Internet]. John Wiley & Sons, Ltd; 2015 [cited 2019 Mar 16];4:1214–22. Available from: http://doi.wiley.com/10.5966/sctm.2015-0079
  35. 35.
    Pagliuca FW, Millman JR, Gürtler M, Segel M, Van Dervort A, Ryu JH, et al. Generation of functional human pancreatic β cells in vitro. Cell [Internet]. Cell Press; 2014 [cited 2019 Mar 16];159:428–39. Available from: https://www.sciencedirect.com/science/article/pii/S0092867414012288 CrossRefGoogle Scholar
  36. 36.
    Millman JR, Xie C, Van Dervort A, Gürtler M, Pagliuca FW, Melton DA. Generation of stem cell-derived β-cells from patients with type 1 diabetes. Nat Commun [Internet]. 2016 [cited 2019 Mar 25];7:11463. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27163171
  37. 37.
    Nair GG, Liu JS, Russ HA, Tran S, Saxton MS, Chen R, et al. Recapitulating endocrine cell clustering in culture promotes maturation of human stem-cell-derived β cells. Nat Cell Biol [Internet]. Nature Publishing Group; 2019 [cited 2019 Apr 17];21:263–74. Available from: http://www.nature.com/articles/s41556-018-0271-4 CrossRefGoogle Scholar
  38. 38.
    Rodrigues AL, Rodrigues CA V., Gomes AR, Vieira SF, Badenes SM, Diogo MM, Cabral JMS Dissolvable microcarriers allow scalable expansion and harvesting of human induced pluripotent stem cells under xeno-free conditions. Biotechnol J [Internet]. 2018 [cited 2019 Mar 25];1800461. Available from: http://doi.wiley.com/10.1002/biot.201800461
  39. 39.
    Rodrigues CA, Silva TP, Nogueira DE, Fernandes TG, Hashimura Y, Wesselschmidt R, et al. Scalable culture of human induced pluripotent cells on microcarriers under xeno-free conditions using single-use vertical-wheel™ bioreactors. J Chem Technol Biotechnol [Internet]. John Wiley & Sons, Ltd; 2018 [cited 2019 Apr 17];93:3597–606. Available from: http://doi.wiley.com/10.1002/jctb.5738
  40. 40.
    Viacyte, Inc. [Internet]. [cited 2019 Apr 17]. Available from: https://viacyte.com/
  41. 41.
    Semma Therapeutics [Internet]. [cited 2019 Apr 17]. Available from: http://www.semma-tx.com/.
  42. 42.
    Seraxis [Internet]. [cited 2019 Apr 17]. Available from: https://www.seraxis.com/
  43. 43.
    Pullen LC. Stem cell-derived pancreatic progenitor cells have now been transplanted into patients: report from IPITA 2018. Am J Transplant [Internet]. 2018 [cited 2019 Apr 17];18:1581–2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29979835 CrossRefGoogle Scholar
  44. 44.
    ViaCyte announces first patients implanted in cohort 2 with potentially efficacious dose of PEC-direct islet cell replacement therapy – Viacyte, Inc. [Internet]. [cited 2019 Jul 2]. Available from: https://viacyte.com/archives/press-releases/cohort2-and-biotech-showcase.
  45. 45.
    Wallner K, Pedroza RG, Awotwe I, Piret JM, Senior PA, Shapiro AMJ, et al. Stem cells and beta cell replacement therapy: a prospective health technology assessment study. BMC Endocr Disord [Internet]. 2018 [cited 2019 Mar 25];18:6. Available from: https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-018-0233-7
  46. 46.
    Jenkins MJ, Farid SS. Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies. Biotechnol J [Internet]. John Wiley & Sons, Ltd; 2015 [cited 2019 Apr 30];10:83–95. Available from: http://doi.wiley.com/10.1002/biot.201400348
  47. 47.
    •• Bandeiras C, Cabral JMS, Gabbay RA, Finkelstein SN, Ferreira FC. Bringing stem cell-based therapies for type 1 diabetes to the clinic: early insights from bioprocess economics and cost-effectiveness analysis. Biotechnol J [Internet]. John Wiley & Sons, Ltd; 2019 [cited 2019 Jun 25];1800563. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/biot.201800563. This paper reports a comprehensive bioprocess model of manufacturing of beta cells from pluripotent stem cells to be encapsulated as type 1 diabetes therapies, in combination with a cost-effectiveness analysis. The findings elicit the critical need for a manufacturing cost reduction to enable widespread cost-effectiveness of stem cell-based therapies.
  48. 48.
    Sambathkumar R, Migliorini A, Nostro MC. Pluripotent stem cell-derived pancreatic progenitors and β-like cells for type 1 diabetes treatment. Physiology [Internet]. 2018 [cited 2019 Mar 25];33:394–402. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30303772
  49. 49.
    Johnston J, Zacharias RL. US stem cell research policy. Princ Regen Med [Internet]. Academic Press; 2019 [cited 2019 Jun 25];1309–29. Available from: https://www.sciencedirect.com/science/article/pii/B9780128098806000758.
  50. 50.
    Beers J, Linask KL, Chen JA, Siniscalchi LI, Lin Y, Zheng W, et al. A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture. Sci Rep [Internet]. Nature Publishing Group; 2015 [cited 2019 Jun 25];5:11319. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26066579

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Cátia Bandeiras
    • 1
    • 2
    • 3
  • Albert J. Hwa
    • 4
  • Joaquim M. S. Cabral
    • 1
    • 2
  • Frederico Castelo Ferreira
    • 1
    • 2
  • Stan N. Finkelstein
    • 3
    • 5
  • Robert A. Gabbay
    • 4
    Email author
  1. 1.Department of Bioengineering and iBB – Institute for Bioengineering and Biosciences, Instituto Superior TécnicoUniversidade de LisboaLisbonPortugal
  2. 2.The Discoveries Center for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior TécnicoUniversidade de LisboaLisbonPortugal
  3. 3.Division of Clinical Informatics, Department of MedicineBeth Israel Deaconess Medical CenterBostonUSA
  4. 4.Joslin Diabetes CenterHarvard Medical SchoolBostonUSA
  5. 5.Institute for Data, Systems and SocietyMassachusetts Institute of TechnologyCambridgeUSA

Personalised recommendations